MODIFICATION
B -- Services Regarding Testicular Dysgenesis Syndrome Among Swedish Familiies
- Notice Date
- 8/20/2009
- Notice Type
- Modification/Amendment
- NAICS
- 518210
— Data Processing, Hosting, and Related Services
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-90176-MM
- Archive Date
- 9/18/2009
- Point of Contact
- Melissa P Marino, Phone: 301-402-4509, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
marinome@mail.nih.gov, cr214i@nih.gov
(marinome@mail.nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- *Modified to change the due date. The National Institutes of Health (NIH), National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), intends to procure on a sole-source basis for services regarding Testicular Dysgenesis Syndrome among Swedish families with the Department of Medicine, Karolinska Institute, Karolinksa University Hospital, M9:01, SE-171 76 Stockholm, Sweden. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-(b)(1). The North American Industry Classification System Code is 518210 and the business size standard is $25.0M. The period of performance is four (4) months from date of award. This is a firm fixed price type contract. In 2001, the existence of the Testicular Dysgenesis Syndrome (TDS) was first hypothesized by Niels Skakkebaek and colleagues (Skakkebaek N et al., Hum Reprod 2001;16:972-8). The hypothesis suggested that two reproductive disorders of newborn males (cryptorchidism, hypospadias) and two reproductive disorders of young adult males (impaired spermatogenesis, testicular germ cell tumors) comprised TDS and had a common origin in fetal life. Since 2001, the existence of the TDS has become increasingly widely accepted by researchers, although supporting human data are still notably lacking. While it is clear that some of the disorders are linked (e.g., cryptorchism and testicular germ cell tumors), there is much less evidence of an association between some of the other disorders (e.g., hypospadias and testicular germ cell cancer, impaired spermatogenesis and hypospadias). In addition, whether the disorders share common perinatal risk factors remained conjectural. As the acceptance of TDS is becoming entrenched in the scientific literature, it is important at this time to examine the relationship between the disorders and the evidence that they are part of a syndrome and have a common origin in fetal life. This project is an expansion of a current NCI study in order to examine whether the TDS disorders (cryptorchidism, hypospadias, impaired spermatogenesis and testicular germ cell tumors) and their putative risk factors aggregate among Swedish families. The specific objective of this procurement is to link the Swedish Cancer Register, the Swedish Hospital Discharge Register, the Swedish Multi-Generation Register and the Swedish Register of Population and Population Changes in order to expand the NCI dataset which will enable the examination of a number of hypotheses of interest. The contractor shall link the records of the Swedish Cancer Register to the records of the Swedish Hospital Discharge Register. The contractor shall obtain data on preexisting medical conditions (e.g. congentical anomalies, testicular trauma, infertility and other related medical conditions) for all men with diagnosis of a testicular germ cell tumor and all matched controls. The most scientifically rigorous study design to examine co-occurrence of male reproductive disorders is to link medical records databases in a country with a high incidence of the disorders. Sweden is the ideal country for such a study as it has nationwide medical records databases of long standing, a high incidence of the disorders under study and has an excellent testicular cancer research group who are highly skilled at linking the databases. Other countries with nationwide medical records databases have smaller populations, lower incidences of the disorders and/or few researchers with experience linking the databases. The Karolinska Institute is uniquely positioned to accomplish this important work as they are the premier testicular cancer research group in Sweden. This is not a solicitation for competitive quotations. However, if any interested party believes it can meet the above requirement, they may submit a statement of capabilities. All information furnished shall be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI contracting office on or before 11:00 AM EST on September 3, 2009. All questions must be in writing and can be faxed to (301) 402-4513 or emailed to Melissa Marino, Contract Specialist at marinome@mail.nih.gov. It is the vendor's responsibility to call (301) 402-4509 to verify questions have been received. A determination by the Government not to compete this proposed acquisition based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration/certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference NCI-90176-MM on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-90176-MM/listing.html)
- Record
- SN01920328-W 20090822/090821001503-12f28b320603fd3dbc288ee973584cf2 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |